Morning Call, May 23
Health Care: Drugs
Lexicon Pharmaceuticals Inc. (LXRX: NASDAQ)
$2.15 0.02 | 0.94%
05/23/13 - 01:19 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -110.21M | -116.22M | -101.78M | -93.32M |
| Operating Gains/Losses | 0.00 | 0.00 | -141.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.03M | 394.00K | 488.00K | -247.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -995.00K | 10.36M | -5.24M | -2.79M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -197.00K | 319.00K | -946.00K | -4.63M |
| Other Non-Cash Items | 16.38M | 13.18M | 9.19M | 4.54M |
| Net Cash From Continuing Operations | -94.46M | -87.94M | -82.37M | -89.02M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -94.46M | -87.94M | -82.37M | -89.02M |
| Sale of Property, Plant & Equipment | 85.00K | 2.62M | 64.00K | 107.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 76.34M |
| Purchases of Property, Plant & Equipment | -492.00K | -1.21M | -1.13M | -369.00K |
| Acquisitions | 0.00 | 0.00 | -5.56M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -59.96M |
| Other Cash from Investing Activities | 0.00 | 176.63M | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -97.81M | 69.96M | -113.84M | 11.88M |
| Issuance of Debt | 0.00 | 0.00 | 11.38M | 38.59M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 38.11M | 160.78M | 181.50M | 55.44M |
| Repayment of Long-Term Debt | -1.44M | -3.59M | -49.86M | -2.12M |
| Repurchase of Capital Stock | -285.00K | -108.00K | -149.00K | -88.00K |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 36.38M | 157.08M | 142.87M | 91.82M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -155.89M | 139.10M | -53.35M | 14.68M |
Portfolios with LXRX
- Portfolio NameUser Type
- UserMy stocks
- ContributorStocks With Big Insider Buy...
- UserMy SP portfolio
- UserWatch
- ContributorStocks Under-$10 Setting Up...
- Contributor22 Biopharma Stocks With Br...
- ContributorStocks Under-$10 Moving Hig...
- Contributor8 Health Care Stocks With R...
- Userhpats Portfolio 1
- Userpkc89
Latest LXRX Headlines from TheStreet
- Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnership 04.29.13 | 11:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- 10 Stocks Insiders And Hedge Funds Think Will Go Higher 03.11.13 | 01:03 pm
- Still Bullish on BioMarin, Lexicon Pharma 11.07.12 | 11:11 am
- 5 Stocks Insiders Love Right Now 10.31.12 | 02:10 pm
- Lexicon Pharma: Blockbuster Potential From A Diabetes Drug 10.16.12 | 06:10 am
- Lexicon Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.11.12 | 02:09 pm
- Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript) 08.14.12 | 05:08 pm
- Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.31.12 | 02:07 pm
Press Releases for LXRX
- Lexicon To Present At The Cowen Healthcare Conference - PR Newswire 03.01.13 | 06:03 am
- Lexicon To Present At The RBC Capital Markets Healthcare Conference - PR Newswire 02.25.13 | 06:02 am
- Lexicon To Report Fourth Quarter And Year End 2012 Financial Results On February 21, 2013 - PR Newswire 02.18.13 | 06:02 am
- Lexicon To Present At The BIO CEO & Investor Conference - PR Newswire 02.06.13 | 06:02 am
- Lexicon To Present At The J.P. Morgan Healthcare Conference - PR Newswire 01.03.13 | 06:01 am
- Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA - PR Newswire 12.17.12 | 06:12 am
- Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference - PR Newswire 11.20.12 | 06:11 am
- Lexicon Pharmaceuticals To Present At The Jefferies 2012 Global Healthcare Conference - PR Newswire 11.12.12 | 06:11 am
- LX4211 Phase 2b Results Presented At American Heart Association Annual Conference - PR Newswire 11.06.12 | 10:11 am
- Lexicon To Provide Third Quarter 2012 Financial Results - PR Newswire 10.31.12 | 06:10 am
Partner Headlines for LXRX
- Investors Wait On Developments For Lexicon Pharmaceuticals - Seeking Alpha 01.03.13 | 08:01 am
- Three Compelling Biopharma Stocks For 2013 - Seeking Alpha 12.26.12 | 09:12 am
- Top 5 Stocks With Insider Buys Filed During The Week Ending October 26 - Seeking Alpha 10.28.12 | 07:10 am
- Lexicon Prices 17.5M Shares At $2.25 per Share - Benzinga 10.18.12 | 09:10 am
- Will Lexicon Pharmaceuticals's Top Institutional Shareholders DOUBLE DOWN on These Hot Catalysts? - Wall St. Cheat Sheet 06.29.12 | 12:06 pm
- Healthcare Biz Review: Icahn SUES Forest, eHealth's EXCELLENT News - Wall St. Cheat Sheet 06.29.12 | 09:06 am
- Comcast's OLYMPIC Strategy and 4 Buzzing Stocks to Know Friday - Wall St. Cheat Sheet 06.29.12 | 09:06 am
- Apollo Group SPIKES 10% to Lead These 5 NASDAQ Top Percentage Winners - Wall St. Cheat Sheet 06.27.12 | 10:06 am
- Wall St. Watchdog Stock Analysts Reiterated Their Ratings of These 3 Shares Today - Wall St. Cheat Sheet 06.26.12 | 03:06 am
- Lexicon UPBEAT Regarding Drug Trial and 4 HOT Analyst Alerts - Wall St. Cheat Sheet 06.26.12 | 02:06 am
